Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 1
1981 1
1992 1
1993 2
1994 1
1995 3
1996 2
1997 2
1999 3
2000 3
2001 4
2002 6
2003 7
2004 6
2005 7
2006 12
2007 9
2008 11
2009 9
2010 13
2011 19
2012 18
2013 16
2014 18
2015 10
2016 21
2017 24
2018 19
2019 19
2020 23
2021 19
2022 16
2023 21
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Results by year

Filters applied: . Clear all
Page 1
ZygosityPredictor.
Rheinnecker M, Fröhlich M, Rübsam M, Paramasivam N, Heilig CE, Fröhling S, Schlenk RF, Hutter B, Hübschmann D. Rheinnecker M, et al. Among authors: schlenk rf. Bioinform Adv. 2024 Feb 6;4(1):vbae017. doi: 10.1093/bioadv/vbae017. eCollection 2024. Bioinform Adv. 2024. PMID: 38560552 Free PMC article.
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3).
Jung S, Schlenk RF, Hackenbruch C, Roldan Pinzon SSL, Bitzer M, Pflügler M, Walz JS, Jung G, Heitmann JS, Salih HR. Jung S, et al. Among authors: schlenk rf. Front Oncol. 2024 Feb 12;14:1351901. doi: 10.3389/fonc.2024.1351901. eCollection 2024. Front Oncol. 2024. PMID: 38410109 Free PMC article.
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Eissymont O, Crysandt M, Görner M, Kayser S, Krause S, Schliemann C, Gaska T, Kaufmann M, Chemnitz J, Schaich M, Hoellein A, Platzbecker U, Kieser M, Müller-Tidow C, Schlenk RF. Jaramillo S, et al. Among authors: schlenk rf. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284346. Online ahead of print. Haematologica. 2024. PMID: 38385304 Free article.
Differential Immunoexpression of Inhibitory Immune Checkpoint Molecules and Clinicopathological Correlates in Keratoacanthoma, Primary Cutaneous Squamous Cell Carcinoma and Metastases.
Lonsdorf AS, Edelmann D, Albrecht T, Brobeil A, Labrenz J, Johanning M, Schlenk RF, Goeppert B, Enk AH, Toberer F. Lonsdorf AS, et al. Among authors: schlenk rf. Acta Derm Venereol. 2024 Feb 7;104:adv13381. doi: 10.2340/actadv.v104.13381. Acta Derm Venereol. 2024. PMID: 38323498 Free PMC article.
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
Kayser S, Sartor C, Giglio F, Bruno A, Webster J, Chiusolo P, Saraceni F, Guerzoni S, Pochintesta L, Borlenghi E, Marconi G, Zacheo I, Cerrano M, Salutari P, Restuccia F, Abbenante M, Levis MJ, Schlenk RF, Papayannidis C. Kayser S, et al. Among authors: schlenk rf. Haematologica. 2024 May 1;109(5):1385-1392. doi: 10.3324/haematol.2023.284310. Haematologica. 2024. PMID: 38058184 Free PMC article.
NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology.
Mock A, Teleanu MV, Kreutzfeldt S, Heilig CE, Hüllein J, Möhrmann L, Jahn A, Hanf D, Kerle IA, Singh HM, Hutter B, Uhrig S, Fröhlich M, Neumann O, Hartig A, Brückmann S, Hirsch S, Grund K, Dikow N, Lipka DB, Renner M, Bhatti IA, Apostolidis L, Schlenk RF, Schaaf CP, Stenzinger A, Schröck E, Hübschmann D, Heining C, Horak P, Glimm H, Fröhling S. Mock A, et al. Among authors: schlenk rf. NPJ Precis Oncol. 2023 Oct 26;7(1):109. doi: 10.1038/s41698-023-00458-w. NPJ Precis Oncol. 2023. PMID: 37884744 Free PMC article.
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase.
Heudobler D, Luke F, Hahn J, Grube M, Schlosser P, Kremers S, Sudhoff T, Westermann J, Hutter-Kronke ML, Schlenk RF, Weber D, Paschka P, Zeman F, Dohner H, Herr W, Reichle A, Thomas S. Heudobler D, et al. Among authors: schlenk rf. Haematologica. 2024 Apr 1;109(4):1274-1278. doi: 10.3324/haematol.2023.283864. Haematologica. 2024. PMID: 37881883 Free PMC article. No abstract available.
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Jaramillo S, Le Cornet L, Kratzmann M, Krisam J, Görner M, Hänel M, Röllig C, Wass M, Scholl S, Ringhoffer M, Reichart A, Steffen B, Kayser S, Mikesch JH, Schaefer-Eckart K, Schubert J, Geer T, Martin S, Kieser M, Sauer T, Kriegsmann K, Hundemer M, Serve H, Bornhäuser M, Müller-Tidow C, Schlenk RF. Jaramillo S, et al. Among authors: schlenk rf. Trials. 2023 Sep 15;24(1):591. doi: 10.1186/s13063-023-07421-x. Trials. 2023. PMID: 37715270 Free PMC article. Clinical Trial.
307 results